Showing 14,501 - 14,520 results of 47,188 for search '(( 50 ((we decrease) OR (a decrease)) ) OR ( 5 ((wt decrease) OR (mean decrease)) ))', query time: 1.24s Refine Results
  1. 14501
  2. 14502

    Associations of baseline plasma BK and the sum of all unmodified bradykinin peptides with the ratio (5-year/baseline) of Sv(PGBM/glom) in the 243 RASS participants. by Kevin M. Wheelock (4237609)

    Published 2017
    “…Values above the dashed line reflect an increase in Sv(PGBM/glom) and those below the line a decrease over 5 years.</p>…”
  3. 14503
  4. 14504
  5. 14505
  6. 14506
  7. 14507
  8. 14508
  9. 14509

    Parthenolide Derivatives as PKM2 Activators Showing Potential in Colorectal Cancer by Xingchen Liu (524190)

    Published 2021
    “…In this study, we designed a series of parthenolide (PTL) derivatives through a stepwise structure optimization, and an excellent derivate <b>29e</b> showed good activity on PKM2 (AC<sub>50</sub> = 86.29 nM) and displayed significant antiproliferative activity against HT29 (IC<sub>50</sub> = 0.66 μM) and SW480 (IC<sub>50</sub> = 0.22 μM) cells. …”
  10. 14510

    Parthenolide Derivatives as PKM2 Activators Showing Potential in Colorectal Cancer by Xingchen Liu (524190)

    Published 2021
    “…In this study, we designed a series of parthenolide (PTL) derivatives through a stepwise structure optimization, and an excellent derivate <b>29e</b> showed good activity on PKM2 (AC<sub>50</sub> = 86.29 nM) and displayed significant antiproliferative activity against HT29 (IC<sub>50</sub> = 0.66 μM) and SW480 (IC<sub>50</sub> = 0.22 μM) cells. …”
  11. 14511

    Parthenolide Derivatives as PKM2 Activators Showing Potential in Colorectal Cancer by Xingchen Liu (524190)

    Published 2021
    “…In this study, we designed a series of parthenolide (PTL) derivatives through a stepwise structure optimization, and an excellent derivate <b>29e</b> showed good activity on PKM2 (AC<sub>50</sub> = 86.29 nM) and displayed significant antiproliferative activity against HT29 (IC<sub>50</sub> = 0.66 μM) and SW480 (IC<sub>50</sub> = 0.22 μM) cells. …”
  12. 14512

    Parthenolide Derivatives as PKM2 Activators Showing Potential in Colorectal Cancer by Xingchen Liu (524190)

    Published 2021
    “…In this study, we designed a series of parthenolide (PTL) derivatives through a stepwise structure optimization, and an excellent derivate <b>29e</b> showed good activity on PKM2 (AC<sub>50</sub> = 86.29 nM) and displayed significant antiproliferative activity against HT29 (IC<sub>50</sub> = 0.66 μM) and SW480 (IC<sub>50</sub> = 0.22 μM) cells. …”
  13. 14513

    Parthenolide Derivatives as PKM2 Activators Showing Potential in Colorectal Cancer by Xingchen Liu (524190)

    Published 2021
    “…In this study, we designed a series of parthenolide (PTL) derivatives through a stepwise structure optimization, and an excellent derivate <b>29e</b> showed good activity on PKM2 (AC<sub>50</sub> = 86.29 nM) and displayed significant antiproliferative activity against HT29 (IC<sub>50</sub> = 0.66 μM) and SW480 (IC<sub>50</sub> = 0.22 μM) cells. …”
  14. 14514
  15. 14515
  16. 14516
  17. 14517
  18. 14518

    PRISMA flow diagram. by Apoorva Anand (17921197)

    Published 2024
    “…Lower sensitivity was attributed to absence of symptoms, errors in test conduct and absence of supervision or a digital support. We found no difference in COVIDST sensitivity between delta and omicron pre-dominant period. …”
  19. 14519

    Aβ-induced BACE1 mRNA and protein expressions in activated N2a Swe cells and their reductions by taxifolin and cilostazol. by So Youn Park (141327)

    Published 2016
    “…Significant decreases in BACE1 protein expression by taxifolin (50 or 100 μM), cilostazol (30 μM), and by 30 μM quercetin (a flavonoid) after 24 hr of treatment. …”
  20. 14520

    Table1_Effectiveness of dapagliflozin as an insulin adjunct in type 1 diabetes: a semi-mechanistic exposure-response model.DOC by Victor Sokolov (14181554)

    Published 2023
    “…Even so, this association remained flat, with a 50% decrease in the basal insulin dose from pretreatment level, resulting in ∼5% increase in glucose exposure. …”